Navigation Links
Mylan Launches Generic Version of Sandostatin®
Date:4/5/2011

PITTSBURGH, April 5, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Bioniche Pharma has launched Octreotide Acetate Injection USP, pre-filled syringes (PFS), the generic version of Novartis' Sandostatin®, a treatment for a rare hormonal disorder called acromegaly. Octreotide Acetate Injection is also used to suppress or inhibit severe diarrhea associated with metastatic carcinoid tumors and vasoactive intestinal peptide tumors.

Mylan Institutional President Matt Erick said: "This approval is particularly important because it is the first and only PFS for this product – brand or generic – providing hospitals and clinics access to a preferred presentation that offers ease, accuracy and convenience of dosing. The addition of Octreotide Acetate Injection as Mylan Institutional's first PFS is a critical next step in expanding our already diverse portfolio of injectable products."

Octreotide Acetate Injection had U.S. sales of approximately $579 million for the 12 months ending Dec. 31, 2010, according to IMS Health. The product, which is available for immediate shipment, was developed by Chemi and is being manufactured by Italfarmaco; both companies are part of privately held Italian Pharmaceutical Group.

Bioniche Pharma is part of Mylan Institutional, a platform that provides differentiated pharmaceutical products to institutional customers throughout North America. Mylan Institutional's product offering includes the specialty injectables of Bioniche Pharma with the unit dose capabilities of Mylan's UDL Laboratories. Mylan Institutional's customers include group purchasing organizations, wholesalers, hospitals, surgical and radiology services, home infusion service providers, long-term care facilities, correctional facilities, specialty pharmacies, veterinary clinics and retail outlets.

Currently, Mylan has
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
2. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
3. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
4. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
5. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
6. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
7. Mylan Confirms Four First-to-File Challenges
8. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
9. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... California and HILDEN, Germany ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... of its QIAGEN Clinical Insight ® (QCI™) ... labs to interpret and report on genomic variants ... supported applications for the bioinformatics platform are in ...
(Date:5/26/2015)... 2015 Global Stem Cells Group ... for the company’s first cellular and regenerative medicine symposium ... full day, hands-on stem cell training class Oct. 10. ... Gimenez, M.D., President of Therapeutic Confrontations (CONFTERA) in Barcelona. ... interest in regenerative medicine and recent advances in cellular ...
(Date:5/26/2015)... 2015 Leading Regenerative Veterinary Medicine® ... long-term relationship with Veterinary Growth Partners, a membership ... to provide access to vital services to veterinary ... VGP as a dedicated partner in bringing stem ... Concentrating and using stem cells natural abilities to ...
(Date:5/26/2015)... 2015 /PRNewswire/ - Fluorinov Pharma (Fluorinov), a FACIT portfolio ... Beshar to its Board of Directors.  His appointment ... expertise as Fluorinov accelerates its clinical development activities.  ... is a pleasure to welcome Luke to the Board ... the strategy, financial strength and success of multiple organizations," ...
Breaking Biology Technology:QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 2VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 3Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3
... 3 Cardiac Science,(Nasdaq: CSCX ) ... rehabilitation, and informatics products, announced the,appointment today ... President and Chief,Operating Officer., (Logo: ... position to build our strategic capabilities at ...
... drug discovery research and high throughput screening applications, global market for ... by 2015. A key driving force is the increasing involvement of ... ... San Jose, CA (PRWEB) November 3, 2008 -- Playing ...
... researchers have synthesized an elusive metal-hydroxide compound in ... way for improved precursor inks that could boost ... to a "bottom-up" production of possibly the first ... nitroso-butylamine as an additive in place of nitrosobenzene. ...
Cached Biology Technology:Cardiac Science Appoints Dave Marver as Chief Operating Officer 2Cardiac Science Appoints Dave Marver as Chief Operating Officer 3Microplate Instrumentation & Supplies Market to Exceed $5.0 Billion by 2015, According to New Report by Global Industry Analysts, Inc 2Microplate Instrumentation & Supplies Market to Exceed $5.0 Billion by 2015, According to New Report by Global Industry Analysts, Inc 3New nanocluster to boost thin films for semiconductors 2
(Date:5/5/2015)... May 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, reminds investors and media ... Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held ... The three-day conference is organized into a ... in is themed Global Fraud: Where is the Trust ...
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/20/2015)... The announcement comes as demand for fire vault ... Ireland,s foremost records management company, has secured ... impressive track record of clients within the first 12 months, ... sector in Dubai . As a result, ... a further eight staff members at its Irish headquarters. The ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... lasers. We use them to print out documents, play CDs ... monitor our bloodstream, and even remove tumors from our bodies. ... Physics IAF in Freiburg have developed the technology for a ... of infrared laser forms the core of an analysis ...
... the sacred beetles of ancient Egypt the scarab beetle group ... of the most vulnerable representatives are contained in the flightless ... A recent study published in the open access journal ... distribution from southern Africa. The two new species ...
... has renewed its prestigious Clinical and Translational Science ... (STSI) in the amount of $29 million over ... in genomics, wireless technology and bioinformatics toward individualizing ... between Scripps Health and The Scripps Research Institute ...
Cached Biology News:Lasers offer an automated way to test drinking water 2Lasers offer an automated way to test drinking water 3NIH awards Scripps Translational Science Institute $29 million grant 2NIH awards Scripps Translational Science Institute $29 million grant 3
recombination at attR1 and attR2 sites...
... Streptavidin-Horseradish Peroxidase Conjugate, 2 ... reporter enzyme molecules for ... in situ hybridization applications.High ... & Labeling & Detection, ...
Whole rabbit blood (any breed, either sex) is collected at the time of slaughter and processed immediately at 4C, bottled, frozen and stored at -70C....
Chicken anti-EEA1...
Biology Products: